Prevalence of CYP450 gene variations in patients with type 2 diabetes

Clinical Laboratory

Volumn 56, Issue 7-8, 2010, Pages 311-318

  Weise, Alexander ^a,b   Prause, S ^b   Eidens, M ^b   Weber, M M ^c   Kann, P H ^d   Forst, T ^a,c   Pfutzner A ^a,b  

^a IKFE Institute for Clinical Research and Development   (Germany)

^b PharmGenomics GmbH   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; EDETIC ACID; GENOMIC DNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; REAL TIME POLYMERASE CHAIN REACTION; BLOOD; CROSS-SECTIONAL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PILOT STUDY;

CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DIABETES MELLITUS, TYPE 2; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; POLYMORPHISM, GENETIC; PPAR GAMMA;

EID: 77957368486     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Roses AD. Pharmacogenetics and Drug Development: The Path to safer and more effective Drugs. Nature Rev 2004;5:645-56. (Pubitemid 39150121)
2. Nelson DR, Kamataki T, Waxman DJ et al. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA Cell Biol 1993;12:1-51. (Pubitemid 23064489)
3. Chen S, Chou WH, Blouin RA et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence in clinical outcomes in psychiatry. Clin Pharmacol Ther 1996;60:522-34. (Pubitemid 26414088)
4. Masimirembwa C, Bertilsson L, Johnansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995;57:656-61.
5. Stubbins MJ, Harris LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1997;7:59-64.
6. Bahadur N, Leathart JB, Mutch E, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6-alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002;64:1579-89. (Pubitemid 35333419)
7. Goldstein JA. Clinical relevance of genetic polymorphisms in human CYP2C subfamily. Br J Clin Pharmacol 2001; 52:349-55. (Pubitemid 32939439)
8. Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 2003;17:27-41. (Pubitemid 36241451)
9. Latruffe N, Vamecq J. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism. Biochimie 1997;79:81-94. (Pubitemid 27290347)
10. Pfützner A, Forst T. Pioglitazone, an anti-diabetic drug with the potency to reduce cardiovascular mortality. Expert Opin Pharmacother. 2006;7:463-76. (Pubitemid 43379612)
11. Zinman B. PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone. Diabetes Obes Metab. 2001;3(Suppl 1):S34-43. (Pubitemid 33720704)
12. Weise A, Lambertz U, Thomé N, et al. (2006) A fast and reliable single-run method for genotyping of the human cytochrome P450 2C8 gene for different ethnic groups. Clin Lab. 2006;52(11-12):599-603. (Pubitemid 44883587)
13. Stamer UM, Bayerer B, Wolf S, Hoeft A, Stüber F. et al. (2002) Rapid and Reliable Method for Cytochrome P450 2D6 Genotyping. Clin Chem. 2002 Sep;48(9):1412-7. (Pubitemid 34925775)
14. Müller B, Zöpf K, Bachofer J, Steimer W. et al. (2003) Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR. Clin Chem. 2003 Oct;49 (10):1624-31. (Pubitemid 37194216)
15. Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:597-607. (Pubitemid 32953585)
16. Singh R, Ting JG, Pan Y, Teh LK, Ismail R, Ong CE. Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity. Drug Metab Pharmacokinet. 2008;23:165-174.
17. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;18:CD006063.
18. McDonough AK, Rosenthal RS, Cao X, Saag KG. The effect of thiazolidinediones on BMD and osteoporosis. Nat Clin Pract Endocrinol Metab. 2008;4:507-13.
19. Roden DM, George AL Jr. The Genetic Basis of Variability in Drug Responses. Nature Rev 2002;1:37-44. (Pubitemid 37361402)
20. Röwer S., Bienzle U., Weise A., et al. High prevalence of cytochrome P450 2C8*2 mutation in northern Ghana. Trop. Med. Int. Health 2005;10:1271-3. (Pubitemid 41789681)
21. Dorado P, Cavaco I, Cáceres MC, Piedade R, Ribeiro V, Llerena A. Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. Eur J Clin Pharmacol. 2008;64:967-70.
22. Bozkurt O, de Boer A, Grobbee DE, Heerdink ER, Burger H, Klungel OH. Pharmacogenetics of glucose-lowering drug treatment: a systematic review. Mol Diagn Ther. 2007;11(5):291-302. (Pubitemid 350014793)